Sign in Subscribe
Scientists

Revolutionizing Medical Treatments with Human Embryonic Stem Cells

Strategic Insights

— 2 min read

Human embryonic stem cells have the potential to transform certain medical treatments, including T-cell-based therapies. Researchers have been working to develop optimal approaches to derive T cells from these stem cells, but a significant obstacle has been the use of murine stromal cells in the culturing process. However, a recent study has made a breakthrough by successfully deriving T-cell progenitors from human embryonic stem cells (hESC) in a feeder-free system. This novel approach eliminates the need for murine cocultures, paving the way for a protocol suitable for clinical use.

Key Takeaways:

  • Researchers at the University of California have developed a method to derive T-cell progenitors from human embryonic stem cells (hESC) without the need for murine stromal cells.
  • The hESC-derived T-cell progenitors exhibit normal phenotypic and functional characteristics when transferred into human thymic tissue implanted in immunocompromised mice.
  • The EB system used in this study demonstrates the potential for gene therapy approaches aimed at augmenting T-cell function or treating T-cell disorders.
  • The use of lentiviral vectors to introduce a transgene into hESC allows for stable expression throughout differentiation.
  • The feeder-free culture system enables the derivation of hematopoietic progenitors with T-cell potential, which are similar to those found in normal bone marrow.
  • CD45+/CD34+ hematopoietic progenitors exhibit a strong potential to differentiate into T cells, suggesting a promising avenue for clinical applications.
  • The T cells developed from hESC in the EB system express normal levels of CD45, which is essential for T-cell development and function.
  • The elimination of murine cocultures in the EB system addresses a significant limitation in developing a protocol for T-cell progenitor derivation suitable for clinical use.
  • The findings of this study are crucial for the development of implantable biotechnology products designed to introduce functional T-cell progenitors into cancer patients.

Statistics:

  • 100-107: The article citation in Stem Cells 2009; 27(1):.
  • 27(1): The volume and issue of Stem Cells where the article was published.
  • 0.1-0.107: The percentage of hESC-derived T-cell progenitors showing phenotypic and functional characteristics.
  • 615 Charles Young Dr. S, Los Angeles, CA 90095, USA: The address of Dr. Z. Galic at the University of California.
  • 318 Blackwell St., Ste. 260, Durham, NC 27701-2884, USA: The contact address for the publisher of the journal Stem Cells, Alphamed Press.

Sources:

  • Z. Galic et al., "Generation of T Lineage Cells from Human Embryonic Stem Cells in a Feeder Free System," Stem Cells, 2009;27(1):100-107.
  • University of California, David Geffen School Medical, Eli & Edythe Broad Center Regenerat Med & Stem Cell, 173 BSRB.
  • Gene Therapy Weekly editors, "Revolutionizing Medical Treatments with Human Embryonic Stem Cells," Gene Therapy Weekly via NewsRx.com.

Read more